Clinical Trial Update: A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer [Phase 1]

View source ↗

Summary

Phase I trial evaluating Luxdegalutamide (JSB462) in Japanese patients with metastatic prostate cancer (metastatic castration-resistant prostate cancer); recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Luxdegalutamide (Luxdegalutamide)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Metastatic Prostate Cancer (mCRPC) | Phase 1 | Status: RECRUITING